Casale Thomas B, Gimenez-Arnau Ana Maria, Bernstein Jonathan A, Holden Michael, Zuberbier Torsten, Maurer Marcus
Internal Medicine, Division of Allergy and Immunology, Morsani College of Medicine, University of South Florida, Tampa, FL, 33620, USA.
Dermatology Department, Hospital del Mar Medical Research Institute, Barcelona, Spain.
Dermatol Ther (Heidelb). 2023 Nov;13(11):2573-2588. doi: 10.1007/s13555-023-01040-9. Epub 2023 Sep 30.
Chronic spontaneous urticaria (CSU) is a debilitating inflammatory disorder of the skin, characterized by a fluctuating natural history, a complex mechanism of action, and a significant burden on patients, including effect on quality of life, development of psychosocial disorders, and a range of comorbidities. Recent international guidelines recommend a therapeutic approach of first-line treatment with second generation H1-antihistamines and second-line treatment with the biologic omalizumab. Here, the salient aspects of CSU and current status of data for omalizumab for patients with CSU are reviewed, with a focus on mechanism of action, efficacy and real-world effectiveness (including patient outcomes, response, relapse, and remission), and safety (including consideration of the risk of anaphylaxis). The review also considers recent data on COVID-19, CSU, and omalizumab and presents our perspective on future needs. Overall, the data suggest that omalizumab is an effective and well-tolerated treatment for patients with CSU that provides benefits for a wide range of patients.
慢性自发性荨麻疹（CSU）是一种使人衰弱的皮肤炎症性疾病，其特点是自然病程波动、作用机制复杂，给患者带来重大负担，包括对生活质量的影响、心理社会障碍的发展以及一系列合并症。最近的国际指南推荐采用第二代H1抗组胺药进行一线治疗、生物制剂奥马珠单抗进行二线治疗的治疗方法。在此，对CSU的显著特征以及奥马珠单抗用于CSU患者的数据现状进行综述，重点关注作用机制、疗效和真实世界有效性（包括患者结局、反应、复发和缓解情况）以及安全性（包括对过敏反应风险的考量）。该综述还考虑了关于2019冠状病毒病（COVID-19）、CSU和奥马珠单抗的最新数据，并阐述了我们对未来需求的看法。总体而言，数据表明奥马珠单抗是一种对CSU患者有效且耐受性良好的治疗方法，可为广泛的患者带来益处。
